|
Volumn 157, Issue 1, 2009, Pages 1-3
|
Advances in histamine pharmacology reveal new drug targets
|
Author keywords
CNS; Cognition; Histamine; Immune cells; Inflammation; Schizophrenia
|
Indexed keywords
ANTIHISTAMINIC AGENT;
CIMETIDINE;
FEXOFENADINE;
G PROTEIN COUPLED RECEPTOR;
GSK 189254;
HISTAMINE H3 RECEPTOR;
HISTAMINE H3 RECEPTOR ANTAGONIST;
HISTAMINE H4 RECEPTOR;
HISTAMINE H4 RECEPTOR ANTAGONIST;
HISTAMINE RECEPTOR;
LEVOCETIRIZINE;
RANITIDINE;
UNCLASSIFIED DRUG;
HISTIDINE DECARBOXYLASE;
HRH4 PROTEIN, HUMAN;
CLINICAL TRIAL;
COGNITIVE DEFECT;
HUMAN;
NARCOLEPSY;
NONHUMAN;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PSYCHOSIS;
REVIEW;
SCHIZOPHRENIA;
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;
ANIMAL;
CHEMICAL STRUCTURE;
DRUG ANTAGONISM;
DRUG POTENTIATION;
EDITORIAL;
PHYSIOLOGY;
ANIMALS;
HISTAMINE ANTAGONISTS;
HISTAMINE H3 ANTAGONISTS;
HISTIDINE DECARBOXYLASE;
HUMANS;
MODELS, MOLECULAR;
RECEPTORS, G-PROTEIN-COUPLED;
RECEPTORS, HISTAMINE;
RECEPTORS, HISTAMINE H3;
|
EID: 67149125972
PISSN: 00071188
EISSN: 14765381
Source Type: Journal
DOI: 10.1111/j.1476-5381.2009.00228.x Document Type: Review |
Times cited : (10)
|
References (15)
|